Biogen upgraded to Conviction Buy from Buy at Goldman Sachs Goldman analyst Terence Flynn added Biogen to the Conviction Buy List and maintained a $338 price target saying he continues to see optionality Aducanumab, its lead pipeline Alzheimer's drug. He expects Phase 3 data in Q4 2019/Q1 2020 saying it could be the first disease modifying drugs on the market with a peak sales estimated at $12B. Further, the analyst views MS competition concerns as overdone and said the balance sheet is relatively under-levered
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.